Seattle Genetics has been fighting cancer since 1997, specializing in drugs that work with the immune system to destroy cancer on the cellular level. This treatment can give cancer patients the ability to kill cancer cells without harmful radiation of chemotherapy. The newest and most promising drug is ADCETRIS® (brentuximab vedotin), now approved in more than 60 countries. Seattle Genetics has values involving a passion for helping patients, scientific excellence, and Teamwork. They have more than 250 stations for clinical testing and are one of the leading producers in non-chemo based treatments for cancer.
Thanks to Clay B. Siegal, C.E.O of Seattle Genetics, these drugs are helping patients all across the globe. At 19, his father was diagnosed with brain cancer, and it changed his life forever. It led him to produce some of the most effective cancer-fighting drugs today. Even at 19, he says he was asking his father’s oncologist where he got his medicines and tools to treat his patients. Clay Siegall graduated with a B.S. in Zoology from the University of Maryland then with a Ph.D. in Genetics from George Washington University. He’s grown as a well-known advocate of cancer research, working with the National Cancer Institute, National Institutes of Health, and the Bristol-Myers Squibb Pharmaceutical Research Institute from 1988 to 1997. He worked under Ajit Kumar, Ph.D., professor of biochemistry and molecular biology at the GW School of Medicine and Health Sciences. He gained valuable connections with the National Institutes of Health and started his work in cancer research. He did his follow-up research at the NIH, targeting his studies in cancer therapy. Presently, he has published over 70 studies and holds 15 patents.